UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Cadmium, zinc, and copper leaching rates determined in large monolith lysimeters

The Science of the total environment, 2024-05, Vol.926, p.171482-171482, Article 171482

2024

Volltextzugriff (PDF)

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

The New England journal of medicine, 2019-08, Vol.381 (8), p.727-738

2019

Volltextzugriff (PDF)

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

The New England journal of medicine, 2023-05, Vol.388 (19), p.1739-1754

2023

Volltextzugriff (PDF)

MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells

Haematologica (Roma), 2014-06, Vol.99 (6), p.997

2014

Volltextzugriff (PDF)

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

The lancet oncology, 2018-11, Vol.19 (11), p.1530-1542

2018

Volltextzugriff (PDF)

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2024-01, Vol.403 (10423), p.249-260

2024

Volltextzugriff (PDF)

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Blood, 2023-08, Vol.142 (5), p.446-459

2023

Volltextzugriff (PDF)

Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry

The European respiratory journal, 2023-02, Vol.61 (2), p.2201336

2023

Volltextzugriff (PDF)

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Blood, 2022-11, Vol.140 (Supplement 1), p.842-845

2022

Volltextzugriff (PDF)

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.2639-2639

2021

Volltextzugriff (PDF)

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.71-71

2021

Volltextzugriff (PDF)

POSTER: MDS-572 Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/ Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S185-S185

2023

Volltextzugriff (PDF)

POSTER: MDS-605 Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/ Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S186-S186

2023

Volltextzugriff (PDF)

MDS-605 Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S373-S374

2023

Volltextzugriff (PDF)

MDS-572 Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S371-S371

2023

Volltextzugriff (PDF)

Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long‐term data of the SIGNS study

European journal of haematology, 2017-08, Vol.99 (2), p.169-177

2017

Volltextzugriff (PDF)

miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia

Experimental hematology, 2011-10, Vol.39 (10), p.1030-1042.e7

2011

Volltextzugriff (PDF)

MiR-134-mediated β1 integrin expression and function in mesenchymal stem cells

Biochimica et biophysica acta, 2013-12, Vol.1833 (12), p.3396-3404

2013

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(10)
Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Female
(7)
Male
(7)
Aged
(6)
Hematology
(6)
Middle Aged
(5)
Adult
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Prospective Studies
(4)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)
Bone Marrow
(3)
Imetelstat
(3)
Micrornas - Genetics
(3)
Oncology
(3)
Patients
(3)
Thrombocytopenia
(3)
Transfection
(3)
Anemia
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cadmium, zinc, and copper leaching rates determined in large monolith lysimeters

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA)

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

P732: ANALYSIS OF PATIENT‐REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON‐DEL(5Q) LOWER‐RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

MDS-604 Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents

POSTER: MDS-572 Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/ Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III

POSTER: MDS-604 Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents

POSTER: MDS-605 Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/ Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

MDS-605 Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase 3

MDS-572 Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III

Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long‐term data of the SIGNS study

miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia

MiR-134-mediated β1 integrin expression and function in mesenchymal stem cells

Suchergebnisse filtern